Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Interventional, Phase IV, Open-label, Study to Evaluate the Safety of Palivizumab in Children Less Than 24 Months of Age With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

NCT06851806 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06851806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06851806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Interventional, Phase IV, Open-label, Study to Evaluate the Safety of Palivizumab in Children Less Than 24 Months of Age With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease
Lead sponsor
AstraZeneca
Phase
Not applicable
Overall status
Active, not recruiting
Start date
December 10, 2025
Completion date
February 28, 2027
Enrollment
21 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus (rsv)